Sunitinib
Jump to navigation
Jump to search
Sunitinib (marketed with the brand name Sutent) is a tyrosine kinase inhibitor used to treat renal cell carcinoma (RCC).
In RCC acts on:[1]
- VEGF.
- PDGFbeta.
Use
- Gastrointestinal stromal tumour, imatinib-resistant.[2]
- Renal cell carcinoma - especially clear cell renal cell carcinoma.[3]
See also
References
- ↑ Toon, CW.; Hasovits, C.; Paik, J.; Field, M.; Chou, A.; Hugh, TJ.; Pavlakis, N.; Gill, AJ. (Jul 2014). "Skin rash, a kidney mass and a family mystery dating back to World War II.". Med J Aust 201 (1): 58-60. PMID 24999901.
- ↑ Mulet-Margalef, N.; Garcia-Del-Muro, X. (2016). "Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives.". Onco Targets Ther 9: 7573-7582. doi:10.2147/OTT.S101385. PMID 28008275.
- ↑ Yildiz, I.; Ekenel, M.; Akman, T.; Kocar, M.; Uysal, M.; Kanitez, M.; Varol, U.; Bayoglu, IV. et al. (Aug 2014). "Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.". Anticancer Res 34 (8): 4329-34. PMID 25075067.